Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Orofacial Pain

J. FRICOVÁ1, M. KLÍROVÁ2, V. MASOPUST4, T. NOVÁK2, K. VÉREBOVÁ2, R. ROKYTA3

1Pain Management Center, Department of Anesthesiology and Intensive Care Medicine, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, 2Psychiatric Center, Third Faculty of Medicine, Charles University in Prague, Prague, 3Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University in Prague, Prague, 4Department of Neurosurgery, Military Faculty Hospital, Charles University in Prague, Prague, Czech Republic

Received March 16, 2013
Accepted May 24, 2013

Summary
Repetitive transcranial magnetic stimulation (rTMS) is non-invasive neuromodulation method. We applied rTMS for the treatment of pharmacoresistant chronic orofacial pain. We compared the effect of 10 Hz and 20 Hz stimulation. The study included 23 patients for 20 Hz stimulation and 36 patients for 10 Hz stimulation with pharmacotherapy resistant chronic facial pain aged 33-65 years with pain duration of at least 6 months. Monitoring of treatment effects was performed within 15 minutes of each rTMS application (days 1-5) and finally stimulation (active vs. sham coil). If compared with data with 10 Hz rTMS study (n=36) and with 20 Hz rTMS (n=23) trials using a parallel design. Only the results obtained in a series of five rTMS treatments in the first step (active n=24, sham n=12), that 20 Hz frequency rTMS using a higher intensity (95 % of motor threshold) to be equally effective relative to VAS (Visual analogue scale) and QST (quantitative sensory testing). In conclusions, the better results with the relief of orofacial pain were obtained with 20 Hz stimulation if compared with 10 Hz stimulation. It was proved with subjective (VAS) and objective evaluation (QST). rTMS can be used in the treatment of chronic intractable pain.

Key words
rTMS 10, 20 Hz • Orofacial pain

Introduction
The prevalence of facial pain in the general population was described by Koopman et al. (2009). Causes of orofacial pain include: trigeminal neuralgia, postherpetic neuralgia, cluster headache, occipital neuralgia, local neuralgia, atypical facial pain, glossopharyngeal neuralgia and paroxysmal hemicrania. Peripheral pain mechanisms of orofacial pain are generally similar to other pain located elsewhere in the body. It concerns activation of receptors of sensory neurons, channels and signaling pathways for the transduction and propagation of nociceptive stimuli (Henry and Hargraves 2007, Fregni et al. 2007). Diffuse noxious inhibitory controls (DNIC) are used to explain the pathophysiological mechanism of atypical but not classical trigeminal neuralgia. Atypical trigeminal neuralgia is a rare neuropathic facial pain disorder. DNIC can be triggered using a standard counter-irritation paradigm (i.e., immersion of the arm in painfully cold water) (Leonard et al. 2009). Also orofacial pain with a cardiac origin has been described, these patients describe the pain as non-radiating bilateral mandibular pain (López-López et al. 2012). Wirz et al. (2010) described that chronic orofacial pain lasting more than 6 months was identified in 1,767 patients. 64 % were female, 76 % were between 20 and 59 years old, 66.3 % had changed doctors on multiple occasions, and 29.5 % had psychological comorbidities. The most common causes
of pain were temporomandibular disorders, atypical odontalgia, and atypical facial pain, which accounted for 83.4% of the sample, with purported etiologies of surgery or trauma (52.4%), musculoskeletal disorders (24.2%), prosthetics (11.4%), or psychosomatic causes (11.7%). Secondary pain syndromes were found in 25% of patients. Motor cortex stimulation was used as part of the treatment of intractable facial pain caused by trigeminal nerve pain from the deafferentation following rhizotomy or by deafferentation pain secondary caused by meningioma or postherpetic neuralgia. Esfahani (2011) described the application of motor cortex stimulation on several forms of intractable facial pain. Atypical facial pain can be also treated using upper thoracic dorsal column stimulation. This is based on known effects of spinal cord stimulation for treatment of refractory angina pectoris. The main mechanisms of action of rTMS that leads to pain relief are considered to be: (a) its influence on the reorganization of the homunculus damaged by pain (Borckardt et al. 2007) and (b) the indirect effect on neuronal activity of remote cortical and subcortical structures, causing inhibition of painful sensory information leading to the spinothalamic pathway (Roktya and Hakl 2011). At present, rTMS is considered to be a very promising method for treatment of chronic pain, although many of the stimulation parameters for pain treatment are still not fully established (Rossini and Rossi 2007, Rollnik et al. 2003). A recent meta-analysis (Leung et al. 2009) demonstrated that the application of the coil is usually targeted on the M1 motor cortex; also noted was that the effectiveness of rTMS, in the treatment of pain, increased with increased stimulation frequency, increased with the number of rTMS applications, and increased with the number of pulses during stimulation.

The aim of the study

The aim of parallel, double-blind, randomized study was:
1. to demonstrate the effectiveness of 20 Hz rTMS application (to the contralateral motor cortex of the somatotopic sites corresponding to the location of the pain) in the treatment of patients with chronic orofacial pain syndrome, assessed via subjective evaluation using a visual analogue scale (VAS), objective evaluation using quantitative sensory testing (QST),
2. to compare the effectiveness of treatment relative to placebo rTMS. A double-blind, placebo-controlled trial using a parallel design monitored the ability of rTMS to change the perception of pain intensity and character in the involved area as defined by subjective scales (VAS) and objective assessment instruments, i.e. quantitative sensory testing (QST).

The study evaluated and compared the immediate and delayed effect of high frequency rTMS (>1 Hz) focused on the contralateral motor cortex at the point corresponding to the somatotopic location of pain (Lefaucheur 2006a, b) and compared the results with placebo rTMS, applied using a sham (placebo) coil.

Methods

Methods of data collection

We prospectively enrolled total number of 23 patients (16 Females, 7 Males) with pharmacotherapy resistant chronic facial pain (trigeminal neuralgia, atypical orofacial pain, post-herpetic neuralgia, dental pain) aged 33-65 years (mean age = 50.7 yrs), with pain duration of at least 6 months, while on analgesic medications. Pain medications included: 1. anticonvulsants or benzodiazepines and hypnotics: pregabalin (n=4), gabapentin (n=5), clonazepam (n=1), bromazepam (n=1), zolpidem (n=1), 2. antidepressants: duloxetine (n=2), venlafaxine (n=3), amitriptyline (n=1); 3. opioids: fentanyl (n=2), dihydrocodeine (n=1), oxycodone (n=2) 4. NSAIDs and muscle relaxants: paracetamol (n=2), metamizole (n=1), tizanidine (n=1).

From the set of 23 patients studied, 17 had secondary trigeminal neuralgia, 11 of them were linked to stomatosurgical (dental surgery) events, while 6 patients had secondary neuralgia after surgery or neurosurgery on the head. The remaining 6 patients had a diagnosis of atypical orofacial pain without a clear organic substrate. Patients included in the study met the following inclusion criteria: (a) orofacial pain syndrome, intractable pharmacoresistant pain, which was defined as the persistence of pain despite at least two attempts at pharmacological treatment in the past, both of sufficient dose and sufficient time, (b) stable analgesic medication for at least 1 month before the start of the study and throughout its course and during follow-up evaluation two weeks after completion of rTMS, (c) 18-65 years of age, (d) the absence of severe organic brain damage or other serious diseases, which could interfere with rTMS (epilepsy) and the absence of any metallic implants in the body (restrictions similar to those for an MRI).

During the baseline period, patients were informed, in detail, about the nature of the study, the clinical course and treatment effects. All participants
signed an informed consent, which in its structure and content was fully consistent with the latest version of the Declaration of Helsinki and the study was approved by the local Ethics Committee of the 3rd Faculty of Medicine. As part of the informed consent, patients were informed about possible side effects and possible complications of treatment. Participation in the study was voluntary and without any financial reward. After the initial examination, which included a detailed analysis to determine the type and nature of pain, and on the day prior to starting treatment with rTMS, participants were clinically evaluated using the subjective VAS (Khedr et al. 2005) using a scale of 0 to 10 points (0 representing the absence of pain and 10 being maximum pain) and QST, which set the threshold for thermal and tactile (touch) sensation in the affected facial area. Thermal sensation was assessed using a specially modified device that creates increasing irritation using a stream of warm air (the temperature of which ranged between 44 and 55 °C). Mechanical sensitivity, specifically, tactile threshold, was determined using von Frey hairs (Touch-test sensory evaluators, North Coast Medical).

After inclusion in the study, patients were randomly divided into one of two treatment branches (active arm, n=13 vs. inactive arm (sham), n=10). Monitoring of treatment effects was performed within 15 minutes of each rTMS application (days 1-5) and finally stimulation (active vs. sham coil).

rTMS stimulation was applied using an air-cooled, 70-millimeter coil creating a magnetic field of 1-2 Tesla in a time interval of 100-200 ms using a Magstim Super Rapid stimulator (Magstim, Whitland, United Kingdom). The active group (20 Hz rTMS) received five sessions (applications) continuously during working days (day 1-5). Individual application of rTMS (720 pulses / session) included a 20-36x train of pulses, with an intertrain interval of 1.9 s, using an intensity of 95 % of the motor threshold at intervals of 2 weeks after rTMS treatment (day 21). In all cases, the evaluator was blinded to the type of stimulation (active or shame). Stimulation parameters were chosen based on available data found in published studies, including a previous data from our pilot project, which demonstrated the clinical effect (rated VAS) of serial 10 Hz stimulation using different stimulus intensities, i.e. 85 %, 90 % and 95 % of motor threshold, for a total of 600 pulses / session applied over 5 sessions several days apart with rTMS application focused over the contralateral motor cortex at the point corresponding to the somatotopic localization of pain sites. The area was identified using functional sites, which is an adequate and well-reproducible method for stimulating the motor cortex. The motor threshold intensity was set at the lowest intensity of the device, an intensity at which at least 5 of the 10 stimuli were recorded with electromyography and produced a visually detectable response to stimulation of cortical areas representing somatotopic localization of the abductor pollicis brevis (EMG Neurosign 400) ≥ 50 microvolts. During placebo (sham stimulation), an inactive rTMS was used as a sham coil and was placed in the identical area as the active coil. During sham rTMS stimulation, patients recorded identical experiences (including sound effects, somatic sensations caused by contraction of the muscles of the scalp) as during active stimulation. The direct effect of the magnetic field on the cerebral cortex, however, had minimal effect (Kleinjung et al. 2008).

Statistical analysis

Baseline demographic and clinical characteristics for both groups at baseline and between treatment groups were compared using the unpaired t-test or Mann-Whitney U test for continuous variables and the χ² test or Fisher exact test for categorical variables. Pain levels were assessed at baseline, after each rTMS session and two weeks (2W) after the last session using the VAS and QST. The least square (LS) QST mean changes (with 95 % CI) from baseline to the final rTMS on day 5 and to the end of follow-up on day 21 were compared between groups using the Mann-Whitney U test. Subsequently, the measurement values from each loop (seven time points) were analyzed using repeated analysis of variance measures (RM-ANOVA) and the Greenhouse-Geisser correction for non-sphericity followed by the Bonferroni's multiple comparison post-hoc test. All statistical analyses were performed using Statistica 9.0 (Statsoft, Inc., Tulsa, USA). For the measurement of rTMS effect were used subjective and objective evaluation. For the subjective evaluation the visual analogue scale (VAS) was used. For the objective evaluation the methods of quantitative sensory testing (QST) were used. There were measured or thermical threshold or mechanical pressure threshold (von Frey hairs). The measurements were effectuated after each stimulation.
**Fig. 1.** The clinical effect of 10 Hz rTMS in Visual analog scale comparing active rTMS and sham rTMS (N=36). Data are presented as mean. rTMS – repetitive Transcranial Magnetic Stimulation, A – Active, S – Sham, VAS – Visual Analog Scale of Pain Intensity, B – VAS Baseline, 1-5 – VAS after rTMS 1-5, VAS 2W – VAS after 2 weeks after the end of rTMS. † p≤0.05 intergroup comparison, * p≤0.05 intragroup comparison. ANOVA: F 6,204 = 2.28; p=0.038

**Fig. 2.** The clinical effect of 20 Hz rTMS in Visual analog scale comparing active rTMS and sham rTMS (N=23). Data are presented as mean. rTMS – repetitive Transcranial Magnetic Stimulation, A – Active, S – Sham, VAS – Visual Analog Scale of Pain Intensity, B – Baseline, 1-5 – VAS after rTMS 1-5, 2W – VAS after 2 weeks after the end of rTMS. † p≤0.05 intergroup comparison, * p≤0.05 intragroup comparison

**Fig. 3.** The influence of 20 Hz rTMS on thermic threshold changes in Quantitative sensory Testing comparing active rTMS and sham rTMS (N=23). Data are presented as mean. rTMS – repetitive Transcranial Magnetic Stimulation, A – Active, S – Sham, t (°C) –Temperature evaluated in Celsius degrees, baseline – thermic threshold at baseline, T1-5 – thermic threshold after rTMS 1-5, TW2 – thermic threshold after 2 weeks after the end of rTMS. † p≤0.05 intergroup comparison, * p≤0.05 intragroup comparison
Results

It can be concluded:

1) The real stimulation is more effective than the shame stimulation (Fig. 1, 2, 5).

2) The results from thermic stimulation have no significant difference between real and shame stimulation. In both cases (10, 20 Hz) there are the decreasing of the effect after third stimulation which lasts up to 14 days (Fig. 3).

3) 20 Hz stimulation has significantly stronger effect than 10 Hz stimulation (Fig. 4) which is not sufficiently strong to have the real effect. 20 Hz stimulation during five days has very strong antinociceptive effect. This effect is stabilized only after 20 Hz stimulation after 14 days (Fig. 1, 2, 5).

4) The effects are clearly expressed in VAS evaluation (Fig. 1, 2) and in tactile (von Frey) measurements (Fig. 5) but there is no significant difference in the QST measurement of thermic stimulation (Fig. 3).
Discussion

The use of rTMS in the treatment of chronic intractable pain is reserved for pain that does not respond to analgesics and for pain in which the cause is difficult to remove. If it can be demonstrated to have an analgesic effect, then rTMS could be considered for inclusion in the current methods of pain treatment (Rokyta and Fricová 2012). The advantage of magnetic stimulation is that it is a non-invasive procedure that is not time-consuming. Before rTMS can be routinely used in the treatment of chronic pain, it is necessary to accurately determine the amount and duration for each stimulation session, thereby ensuring the optimal duration of effect. From our results it is possible to conclude that the more effective rTMS was obtained with 20 Hz stimulation if compared with our results with 10 Hz stimulation in our previous pilot study (Fricová et al. 2009). These results were measured with subjective evaluation of the pain, VAS, and with objective measurement using QTS. In objective evaluation the tactile measurement proved to be more important, while the results from measurement of thermal thresholds were not significant. The two treatment groups (active vs. sham) were comparable with respect to baseline demographic and clinical characteristics. rTMS was well tolerated, and no serious adverse effects were reported. In our study we combined both sham or real stimulation. Another advantage over other neuromodulatory methods is the price of the equipment. It has been included among the EFNS (European Federation of Neurological Societies) guidelines for Neurostimulation therapy (Grucu et al. 2007).

rTMS has also been tested on healthy subjects and was found to cause facilitation of motor evoked potentials (Gilio et al. 2009), leading to an alternative interpretation of the effects of rTMS, which involves the activation of plasticity in the cerebral cortex (Ziemann 2004). Another possible pathophysiological explanation is that low-frequency stimulation (1 Hz) reduces the activity of excitatory circuits in the human motor cortex (Di Lazzaro et al. 2008). Our results did not completely confirm this hypothesis. rTMS has also been investigated in depression, Parkinson's disease, spinocerebellar degeneration, epilepsy, urinary incontinence, movement disorders, chronic pain, migraines and chronic tinnitus (Kleinjung et al. 2008, Hausmann et al. 2004). The method did very well in comparison with epidural motor cortex stimulation and transcranial direct current electrical stimulation both in terms of effect and having a favorable cost / effectiveness ratio (Zaghi et al. 2009). rTMS has also been tested in monkeys (Ugawa et al. 2006). Effectiveness of rTMS also depends on the type of neuropathic pain (Leung et al. 2009, Lefaucheur 2006a, b).

Application of rTMS induces not only subjective pain relief (Hirayama et al. 2006, Leung et al. 2009 Lefaucheur 2006a, b) but also objective changes in Quantitative Sensory Testing (QST), namely changes in thermal threshold (Borckardt et al. 2007, Lefaucheur et al. 2008) and the threshold for tactile sensation (Summers et al. 2004, Lefaucheur et al. 2008). Changes in the threshold of tactile sensation can be easily and reliably accessed with techniques using von Frey monofilaments and a Peltier thermal generator can be used to determine changes in thermal threshold (Lefaucheur et al. 2008).

Information regarding the prevalence of orofacial pain varies considerably from study to study and depends on the source of pain, however, it appears to affect between 10 to 50 % of the adult population. The most common cause of facial pain is pain of dental origin, which begins after dental repairation or dental surgeries. Very often it is an intractable pain and pharmacological treatment is unsuccessful. Recent studies have suggested the involvement of the peripheral and central nervous system in the pathophysiology of atypical odontalgia.

Today rTMS is used with short-term success in the treatment of pain, mostly neuropathic pain. Previous studies have confirmed the ability of high (>1 Hz) rTMS to stimulate the M1 (Hirayama et al. 2006, Johnson et al. 2006) in the treatment of facial pain. Valmunen et al. (2009) have shown that the application of rTMS to the M1 changes the thermal pain threshold in this and related areas. Also of interest is the DLPFC (dorsolateral prefrontal cortex) coil position, which seems to have a substantial influence on neuronal circuits involved in the processing of cognitive and emotional aspects of pain.

Other effects of rTMS on pain

1 Hz (low frequency) rTMS reduces acute pain induced by capsaicin temporarily improves phantom pain (Töpper et al. 2003) and reduces pain in fibromyalgia (Sampson et al. 2006). High-frequency rTMS (>1 Hz) has been shown to produce changes in the pain threshold in people with chronic pain (Johnson et al. 2006). Higher frequency rTMS (5-10 Hz) also reduces deafferentation intractable pain in spinal cord injury and in peripheral nerves (Saitoh et al. 2007). We enlarged these indications of high frequency stimulation (>1 Hz) by using 20 Hz stimulation, which was found to be very suitable for
treatment of orofacial pain.

rTMS suppresses the perception of painful CRPS (Complex Regional Pain Syndrome) (Pleger et al. 2004, Picarelli et al. 2010), and suppresses neuropathic pain, in particular pain with a central origin (Leung et al. 2009). rTMS is also effective in treating migraines with or without aura (Conte et al. 2010, Brighina et al. 2005). Low-frequency vertex rTMS (1 Hz) has been shown to have a prophylactic effect on migraines (Teepker et al. 2010).

Our study confirmed that rTMS at a frequency of 20 Hz, functionally localized to the area of the motor cortex contralateral to the position corresponding to the somatotopic location of the pain source is effective in the treatment of chronic orofacial pain. Subjective evaluation of intra- and inter-group VAS scores, compared with the control group, showed both immediate and delayed treatment effects in subsequent measurements. The results of the VAS ratings are consistent with results of previous studies (Lefaucheur et al. 2001, Pleger et al. 2004, Johnson et al. 2006). Changes in thermal sensation were not statistically different between groups. Intragroup comparison confirmed the reduction of thermal threshold for hot air stimulation after repeated rTMS application. Some studies have confirmed the influence of rTMS to reduce the threshold for thermal stimulation of both cold air (Johnson et al. 2006) and hot air (Lefaucheur et al. 2008). Other studies however, have shown an increased thermal threshold for hot air stimulation after rTMS (Johnson et al. 2006). Inter-group comparisons of tactile sensations showed acute effects after repeated stimulation (days 2, 4 and 5) but not when measured using a longer interval (day 21). Confirmation of the influence of rTMS on QST, specifically its ability to reduce the threshold for tactile (mechanical) sensation, supports the hypothesis that modulation of tactile and thermal perception in the painful zone interacts with the analgesic effect of cortical stimulation (Lefaucheur et al. 2008).

Our data are consistent with previous studies which reported that the use of a higher frequency increased number of pulses during an rTMS application and an increased number of applications (Leung et al. 2009) led to increased efficacy of the method in the treatment of pain. The best frequency of stimulation for the most effective pain treatment has not yet been resolved. Our results support the effect of 20 Hz rTMS.

Complications of rTMS

Low frequency rTMS stimulation can cause nausea, probably via stimulation of the posterior cranial fossa (Satow et al. 2002). rTMS of the premotor cortex reduces painful axial spasms in generalized secondary dystonia (Lefaucheur et al. 2004). rTMS can also have side effects and randomly caused convulsions in control patients, one patient was reported to suffer from depression and parietal epilepsy (Rosa et al. 2006). Side effects include induction of epileptic seizures (less than 1% of patients), which is more likely in high-frequency rTMS (>1 Hz) and rarely occurs in low-frequency rTMS (≤1 Hz). A more common problem is the formation of transient pain, which is precisely located and depends on the site of stimulation (Rossi et al. 2009).

Conclusions

rTMS is very useful noninvasive neuromodulation treatment of chronic orofacial pain. We can recommend to use higher stimulatory frequency (20 Hz) than the 10 Hz stimulation.

For rTMS to be routinely used in the treatment of chronic pain, it is necessary to accurately determine the amount and duration of each stimulation, thereby ensuring the optimal efficacy of the method. rTMS is a non-invasive method of neuromodulation, which represents a major breakthrough in neurosurgical approaches to the treatment of pain (Khedr et al. 2005, Johnson et al. 2006).

The method is included among the EFNS (European Federation of Neurological Societies) guidelines for neurostimulation therapy (Cruccu et al. 2007). For treatment of pain that is unresponsive to analgesics and for pain in which the cause of the pain is difficult to remove. If the analgesic effect rTMS can be demonstrated, it could be considered among current methods for pain treatment.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

The study was supported by the project of Charles University PRVOUK P34, by grant of the Ministry of Health – IGA NT 14484-3/2013.
References


